Dr. Reddy's Laboratories Ltd. closed 16.92% below its 52-week high of 1,420.20 rupees, which the company reached on August ...

Dr. Reddy's Laboratories Ltd. 500124 shares slipped 2.23% to 1,197.40 Indian rupees Monday, on what proved to be an ...

Dr Reddy's Laboratories Ltd (RDY) reports a robust 16% YoY revenue growth, driven by strategic product launches and market ...

CEO of Dr Reddy's Laboratories, Erez Israeli believes his company's affordable medicines benefit the U.S. market and will be ...

The generic drugmaker was the top loser on the Nifty Pharma index and the benchmark Nifty 50 index. "The drop in shares comes ...

Stay up-to-date with the Dr Reddys Stock Liveblog, your comprehensive source for real-time updates and detailed analysis on a prominent stock. Explore the latest information on Dr Reddys, including: ...

Q3 2025 Earnings Call Transcript January 23, 2025 Operator: Ladies and gentlemen, good day and welcome to the Quarter Three ...

Dr. Reddy's Lab is poised to witness crosswinds from a drop in revenue from the patent expiration of Revlimid and increased ...

Welcome to the Dr Reddys Stock Liveblog, your ultimate source for real-time updates and analysis of one of the most prominent ...

Barclays analyst Balaji Prasad maintained a Buy rating on Dr Reddy’s Laboratories (RDY – Research Report) today and set a price target of ...

Dr. Reddy's shares in Friday's trade saw a sharp fall following the company's weak set of earnings for the December quarter.

Crossmark Global Holdings Inc. grew its stake in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY – Free Report) by 328.3% in the fourth quarter, Holdings Channel reports. The firm owned 12,760 ...